Generated by AI
AtriCure Inc. is a medical device company that develops and sells surgical technologies for treating atrial fibrillation, managing the left atrial appendage, and controlling post-operative pain. Its portfolio includes ablation systems, left atrial appendage exclusion devices, cryoablation products, and related surgical instruments used in cardiac, thoracic, and electrophysiology procedures. AtriCure’s products are designed for use by cardiothoracic surgeons, electrophysiologists, and medical centers that perform open, minimally invasive, and hybrid cardiac surgeries. The company serves healthcare providers in the United States and international markets, supporting procedure workflows in hospitals and specialized surgical settings. Founded in 2000 and headquartered in Mason, Ohio, AtriCure focuses on device-based therapies that address important needs in rhythm management and surgical pain control.
Website7555 Innovation Way
Mason, OH, 45040
United States
The latest articles about ATRC.
AtriCure expands beyond AF to all open-heart surgeries, with 2027 catalysts, strong profitability, and growth. Click for more on ATRC stock.
Summary of Sep 2's posts. Generated by AI.
No summary yet.
Summary of Apr 28's posts. Generated by AI.
Summary of Apr 25's posts. Generated by AI.
Summary of Oct 28's posts. Generated by AI.
Investors talking about ATRC also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.